ArticleClinical rheumatology2026
Inflammatory and total immunoglobulin biomarker domains in systemic sclerosis vasculopathy: a phenotype-based cross-sectional study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo characterize inflammatory and total immunoglobulin-domain profiles across clinically defined vasculopathy phenotypes in SSc using a phenotype-oriented framework.
methodsIn this retrospective cross-sectional study, 314 patients with SSc fulfilling the 2013 ACR/EULAR criteria were classified into four vasculopathy phenotypes: no DU/gangrene/clinically diagnosed PAH/SRC-defined overt vasculopathy ("none"), peripheral only, visceral only, and mixed. Inflammatory and total immunoglobulin-domain scores were prespecified as the mean of standardised ESR and hs-CRP, and IgG and IgA, respectively. Associations between domain scores and phenotypes were evaluated using adjusted multinomial logistic regression, with prespecified binary and sensitivity analyses used as supportive analyses.
resultsOmnibus comparisons across the four phenotypes, ESR, hs-CRP, CAR, and IgG remained significant after FDR correction, whereas albumin, IgA, and ACA showed nominal differences only. Descriptively, ESR and hs-CRP were higher in visceral-involvement phenotypes, IgG was highest in the visceral-only group, and IgA was highest in the mixed group. In adjusted multinomial models, each 1-SD increase in the inflammatory domain score was associated with visceral-only phenotype versus none (OR 1.49, 95% CI 1.06-2.10, p = 0.021) and mixed phenotype versus none (OR 1.60, 95% CI 1.03-2.47, p = 0.035) in the single-domain model, while each 1-SD increase in the total immunoglobulin-domain score was associated with visceral-only phenotype versus none (OR 1.43, 95% CI 1.02-2.02, p = 0.039). These multinomial associations did not remain robust after FDR correction and were attenuated in the joint-domain model. In the prespecified supportive binary analyses, the clearest associations were observed for visceral involvement versus none: inflammatory domain OR 1.59 (95% CI 1.19-2.14) and total immunoglobulin-domain OR 1.53 (95% CI 1.14-2.06). Sensitivity analyses showed no material direction reversal but indicated attenuation after extended adjustment.
conclusionCirculating inflammatory and total immunoglobulin-domain scores showed a directionally consistent association with clinically defined, predominantly clinically diagnosed PAH-weighted visceral vascular involvement in this inpatient SSc cohort. These exploratory cross-sectional findings require confirmation in prospectively phenotyped cohorts. Key Points • We classified systemic sclerosis vasculopathy into clinically defined phenotypes based on structural peripheral ischaemic damage and clinically diagnosed PAH/SRC-defined visceral vascular involvement. • Circulating inflammatory and total immunoglobulin-domain enrichment was more evident in clinically defined, predominantly PAH-weighted visceral-involvement phenotypes than in peripheral-only disease. • Peripheral-only phenotype, defined narrowly by structural ischaemic damage endpoints, showed limited domain-level enrichment after adjustment. • Attenuation in joint-domain models suggests partial overlap between systemic inflammatory burden and total immunoglobulin-related signals.
Indexed as
Identifiers
42860474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.